CYTK ▼ -6.3% - Cytokinetics, Incorporated $CYTK - Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 Cytokinetics shares fell 6.3% following the company's announcement of additional results from its ACACIA-HCM and MAPLE-HCM trials presented at the European Society of Cardiology Congress. While the headline confirms that results were presented, it does not specify the nature of those results, suggesting the market may have interpreted the data as disappointing or below expectations for the hypertrophic cardiomyopathy programs. 29-AUG-2026 10:30 AM ET